positions available now

Tag Archives: PBAC

November 2018 PBAC Meeting Agenda

The November 2018 PBAC Meeting is scheduled to conclude today. Here, the Commercial Eyes Market Access team provides an analysis of the meeting agenda, including Sponsors with multiple submissions and the nature of requested listings by type.     The … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , | Comments Off on November 2018 PBAC Meeting Agenda

PBAC Meeting Outcomes – July 2018

The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions.   … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , , | Comments Off on PBAC Meeting Outcomes – July 2018

PBAC Special Meeting – August 2018

The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team … Continue reading

Posted in Market Access, PBAC | Tagged , , , , , | Comments Off on PBAC Special Meeting – August 2018

The long road to PBS listing for Orkambi

Orkambi (lumacaftor and ivacaftor), a treatment for cystic fibrosis (CF), will go before the PBAC for a fourth time at the upcoming July 2018 PBAC meeting. So far, the road to reimbursement has been filled with multiple rejections, a strong … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , , , | Comments Off on The long road to PBS listing for Orkambi

PBAC Meeting Agenda – July 2018

The July 2018 PBAC Meeting is scheduled from 4 to 6 Jul 2018. Here, the Commercial Eyes Market Access team provides an overview of the meeting agenda, including submissions relating to biosimilars lodged for this meeting.     The Commercial … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , , , , | Comments Off on PBAC Meeting Agenda – July 2018

PBAC Meeting Outcomes – March 2018

The March 2018 PBAC Meeting Outcomes were published on 20th April 2018. With 71 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including an additional analysis conducted on oncology submissions which have … Continue reading

Posted in Life Sciences Industry, Market Access | Tagged , , , | Comments Off on PBAC Meeting Outcomes – March 2018

PBAC Meeting Agenda – March 2018

  The Commercial Eyes Market Access can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us help … Continue reading

Posted in Market Insight, PBAC | Tagged , | Comments Off on PBAC Meeting Agenda – March 2018

PBAC outcomes: a snapshot of 2017

  The Commercial Eyes Market Access Team can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us … Continue reading

Posted in Market Access, PBAC | Tagged , , | Comments Off on PBAC outcomes: a snapshot of 2017

The PBAC major submission deadline is nearly here. Are you prepared for lodgement?

With the March 2016 major submission deadline looming, a significant but commonly overlooked aspect are the key administrative documents that accompany a lodged submission.  With a number of key documents changing, either in new process or content, as well as … Continue reading

Posted in E-Health/Technology, Market Access, PBAC | Tagged , | Comments Off on The PBAC major submission deadline is nearly here. Are you prepared for lodgement?

Pricing uncertainty within the Pharmaceutical Benefits Scheme

Recent years have seen an active attempt to control Pharmaceutical Benefits Scheme (PBS) costs. Price disclosure and mandatory price cuts upon formulary transition have ensured prices of pharmaceuticals (especially generics) continue to tumble. Yet despite the use of these tools, … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , | Comments Off on Pricing uncertainty within the Pharmaceutical Benefits Scheme
Copyright © 2014 Commercial Eyes